References
- Torre
LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet
MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J
Clin. 2018 Jul;68(4):284-296.
- Coburn SB, Bray F, Sherman ME,
Trabert B. International patterns and trends in ovarian cancer
incidence, overall and by histologic subtype. Int J Cancer. 2017 Jun
1;140(11):2451-2460.
- Zhu JW, Charkhchi P, Akbari MR.
Potential clinical utility of liquid biopsies in ovarian cancer. Mol
Cancer. 2022 May 11;21(1):114.
- Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I,
Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I,
Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian
Cancer Consensus Conference Working Group. ESMO-ESGO consensus
conference recommendations on ovarian cancer: pathology and molecular
biology, early and advanced stages, borderline tumours and recurrent
disease†. Ann Oncol. 2019 May
1;30(5):672-705.
- Oza AM, Cook AD, Pfisterer J,
Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS,
Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR,
Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L,
Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard
chemotherapy with or without bevacizumab for women with newly
diagnosed ovarian cancer (ICON7): overall survival results of a phase
3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36.
- Cancer Genome Atlas Research
Network. Integrated genomic analyses of ovarian carcinoma. Nature.
2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in:
Nature. 2012 Oct 11;490(7419):298.
- Richardson DL, Eskander RN, O’Malley
DM. Advances in Ovarian Cancer Care and Unmet Treatment Needs for
Patients With Platinum Resistance: A Narrative Review. JAMA Oncol.
2023 Jun 1;9(6):851-859.
- VBL
Therapeutics. VBL announces top-line data from phase 3 OVAL trial
of Ofra-Vec in patients with platinum-resistant ovarian cancer.
Accessed September 15, 2023.
- Gaillard S, Oaknin A, Ray-Coquard I,
et al. Lurbinectedin versus pegylated liposomal doxorubicin or
topotecan in patients with platinum-resistant ovarian cancer: a
multicenter, randomized, controlled, open-label phase 3 study
(CORAIL). Gynecol Oncol.2021;163(2):237-245.
- Shepherd J, Blauw GJ, Murphy MB,
Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW,
Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ,
Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group.
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin
in elderly individuals at risk of vascular disease (PROSPER): a
randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-30.
- Xia Y, Xie Y, Yu Z, Xiao H, Jiang G,
Zhou X, Yang Y, Li X, Zhao M, Li L, Zheng M, Han S, Zong Z, Meng X,
Deng H, Ye H, Fa Y, Wu H, Oldfield E, Hu X, Liu W, Shi Y, Zhang Y. The
Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant
Discovery. Cell. 2018 Nov
1;175(4):1059-1073.e21.
- Wang Q, Zhi Z, Han H, Zhao Q, Wang
X, Cao S, Zhao J. Statin use improves the prognosis of ovarian cancer:
An updated and comprehensive meta-analysis. Oncol Lett. 2022 Dec
23;25(2):65.
- Kobayashi
Y, Takeda T, Kunitomi H, Chiwaki F, Komatsu M, Nagai S, Nogami Y,
Tsuji K, Masuda K, Ogiwara H, Sasaki H, Banno K, Aoki D. Response
Predictive Markers and Synergistic Agents for Drug Repositioning of
Statins in Ovarian Cancer. Pharmaceuticals (Basel). 2022 Jan
21;15(2):124.
- Nieman, K. M. et al. Adipocytes
promote ovarian cancer metastasis and provide energy for rapid tumor
growth. Nat. Med.2011;17, 1498–1503.
- Mukherjee A, Bezwada D, Greco F,
Zandbergen M, Shen T, Chiang CY, Tasdemir M, Fahrmann J, Grapov D, La
Frano MR, Vu HS, Faubert B, Newman JW, McDonnell LA, Nezi L, Fiehn O,
DeBerardinis RJ, Lengyel E. Adipocytes reprogram cancer cell
metabolism by diverting glucose towards glycerol-3-phosphate thereby
promoting metastasis. Nat Metab. 2023 Sep;5(9):1563-1577.
- Zhang Y, Wang Y, Zhao G, Orsulic S,
Matei D. Metabolic dependencies and targets in ovarian cancer.
Pharmacol Ther. 2023 May;245:108413.
- de Wolf E, Abdullah MI, Jones SM,
Menezes K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA,
Richardson A. Dietary geranylgeraniol can limit the activity of
pitavastatin as a potential treatment for drug-resistant ovarian
cancer. Sci Rep. 2017 Jul
14;7(1):5410.
- Huang
X, Wei X, Qiao S, Zhang X, Li R, Hu S, Mao H, Liu P. Low Density
Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a
Reductase (HMGCR) Expression are Associated with Platinum-Resistance
and Prognosis in Ovarian Carcinoma Patients. Cancer Manag Res. 2021
Dec 6;13:9015-9024.
- Criscuolo D, Avolio R, Calice G, Laezza C, Paladino S, Navarra G,
Maddalena F, Crispo F, Pagano C, Bifulco M, Landriscina M, Matassa DS,
Esposito F. Cholesterol Homeostasis Modulates Platinum Sensitivity in
Human Ovarian Cancer. Cells. 2020 Mar 30;9(4):828.
- Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, Zaravinos
A. EMT Factors and Metabolic Pathways in Cancer. Front Oncol. 2020 Apr
7;10:499.
- Huang P, Nedelcu D, Watanabe M, Jao C, Kim Y, Liu J, Salic A. Cellular
Cholesterol Directly Activates Smoothened in Hedgehog Signaling. Cell.
2016 Aug 25;166(5):1176-1187.
- Gordon
RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ,
Astsaturov I, Curran T, et al. Statins synergize with hedgehog pathway
inhibitors for treatment of medulloblastoma. Clin Cancer Res.
2018;24(6):1375–88.
- Huang P, Nedelcu D, Watanabe M, Jao
C, Kim Y, Liu J, Salic A. Cellular Cholesterol Directly Activates
Smoothened in Hedgehog Signaling. Cell. 2016 Aug
25;166(5):1176-1187.
- Freed-Pastor W, Prives C. Targeting
mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016 Oct
27;18(11):1122-1124.
- Wang M, Casey PJ. Protein
prenylation: unique fats make their mark on biology. Nat Rev Mol Cell
Biol. 2016 Feb;17(2):110-22.
- Cordle A, Koenigsknecht-Talboo J,
Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated
inhibition of small G-protein function. J Biol Chem. 2005 Oct
7;280(40):34202-9.
- Kato S, Liberona MF, Cerda-Infante
J, Sánchez M, Henríquez J, Bizama C, Bravo ML, Gonzalez P, Gejman R,
Brañes J, García K, Ibañez C, Owen GI, Roa JC, Montecinos V, Cuello
MA. Simvastatin interferes with cancer ’stem-cell’ plasticity reducing
metastasis in ovarian cancer. Endocr Relat Cancer. 2018
Oct;25(10):821-836.
- Yarmolinsky J, Bull CJ, Vincent EE,
Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM.
Association Between Genetically Proxied Inhibition of HMG-CoA
Reductase and Epithelial Ovarian Cancer. JAMA. 2020 Feb
18;323(7):646-655.
- Shoshan-Barmatz V, De Pinto V,
Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional
mitochondrial protein regulating cell life and death. Mol Aspects Med.
2010 Jun;31(3):227-85.
- Campbell AM, Chan SH. Mitochondrial
membrane cholesterol, the voltage dependent anion channel (VDAC), and
the Warburg effect. J Bioenerg Biomembr. 2008 Jun;40(3):193-7.
- Magrì A, Reina S, De Pinto V. VDAC1
as Pharmacological Target in Cancer and Neurodegeneration: Focus on
Its Role in Apoptosis. Front Chem. 2018 Apr 6;6:108.
- Kobayashi Y, Takeda T, Kunitomi H,
Chiwaki F, Komatsu M, Nagai S, Nogami Y, Tsuji K, Masuda K, Ogiwara H,
Sasaki H, Banno K, Aoki D. Response Predictive Markers and Synergistic
Agents for Drug Repositioning of Statins in Ovarian Cancer.
Pharmaceuticals (Basel). 2022 Jan 21;15(2):124.
- Lipper CH, Stofleth JT, Bai F, Sohn
YS, Roy S, Mittler R, Nechushtai R, Onuchic JN, Jennings PA.
Redox-dependent gating of VDAC by mitoNEET. Proc Natl Acad Sci U S A.
2019 Oct 1;116(40):19924-19929.
- Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The
PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Curr Cancer Drug Targets. 2008 May;8(3):187-98.
- Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C,
Bogani G, Ceccacci I, Mueller MD, Benedetti Panici P. PI3K/AKT/mTOR
Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
Geburtshilfe Frauenheilkd. 2017 Oct;77(10):1095-1103.
- Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D,
Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA,
Coukos G, Weber BL, Degenhardt Y. Frequent genetic abnormalities of
the PI3K/AKT pathway in primary ovarian cancer predict patient
outcome. Genes Chromosomes Cancer. 2011 Aug;50(8):606-18.
- Deng CF, Zhu N, Zhao TJ, Li HF, Gu J, Liao DF, Qin L. Involvement of
LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.
Front Oncol. 2022 Feb 16;12:803473.
- Miraglia E, Högberg J, Stenius U. Statins exhibit anticancer effects
through modifications of the pAkt signaling pathway. Int J Oncol. 2012
Mar;40(3):867-75.
- Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of
rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize
p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 2006
Nov;5(11):2706-15.
- Stine JE, Guo H, Sheng X, Han X, Schointuch MN, Gilliam TP, Gehrig PA,
Zhou C, Bae-Jump VL. The HMG-CoA reductase inhibitor, simvastatin,
exhibits anti-metastatic and anti-tumorigenic effects in ovarian
cancer. Oncotarget. 2016 Jan 5;7(1):946-60.
- Zhu L, Chen L. Progress in research on paclitaxel and tumor
immunotherapy. Cell Mol Biol Lett. 2019 Jun 13;24:40.
- Hu D, Yang C, Lok CN, Xing F, Lee PY, Fung YME, Jiang H, Che CM. An
Antitumor Bis(N-Heterocyclic Carbene)Platinum(II) Complex That Engages
Asparagine Synthetase as an Anticancer Target. Angew Chem Int Ed Engl.
2019 Aug 5;58(32):10914-10918.
- Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis AD,
Richardson A. Preclinical evaluation of statins as a treatment for
ovarian cancer. Gynecol Oncol. 2013 May;129(2):417-24.
- Pan Q, Xu J, Ma L. Simvastatin enhances chemotherapy in cervical
cancer via inhibition of multiple prenylation-dependent
GTPases-regulated pathways. Fundam Clin Pharmacol. 2020
Feb;34(1):32-40.
- Gupta VK, Sharma NS, Kesh K, Dauer P, Nomura A, Giri B, Dudeja V,
Banerjee S, Bhattacharya S, Saluja A, Banerjee S. Metastasis and
chemoresistance in CD133 expressing pancreatic cancer cells are
dependent on their lipid raft integrity. Cancer Lett. 2018 Dec
28;439:101-112.
- Tichomirowa MA, Theodoropoulou M, Daly AF, Yassouridis A, Hansen S, Lu
J, Lange M, Goldbrunner RH, Stalla GK, Renner U. Toll-like receptor-4
is expressed in meningiomas and mediates the antiproliferative action
of paclitaxel. Int J Cancer. 2008 Oct 15;123(8):1956-63.
- Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and
paclitaxel in human cancer cells. Mol Cancer Ther. 2001
Dec;1(2):141-9.
- Jin H, He Y, Zhao P, Hu Y, Tao J, Chen J, Huang Y.
Targeting lipid metabolism to
overcome EMT-associated drug resistance via integrin β3/FAK pathway
and tumor-associated macrophage repolarization using
legumain-activatable delivery. Theranostics. 2019 Jan 1;9(1):265-278.
- Lobos N, Lux S, Zepeda RJ, Pelissier T, Marcos JL, Bustos-Quevedo G,
Hernández A, Constandil L. Rosuvastatin Synergistically Enhances the
Antinociceptive Efficacy of Duloxetine in Paclitaxel-Induced
Neuropathic Pain in Mice. Int J Mol Sci. 2023 May 6;24(9):8359.
- Maheshwari RA, Sailor GU, Patel L, Balaraman R. Amelioration of
cisplatin-induced nephrotoxicity by statins. Indian J Pharmacol. 2013
Jul-Aug;45(4):354-8.
- Garcia J, Hurwitz HI, Sandler
AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®)
in cancer treatment: A review of 15 years of clinical experience and
future outlook. Cancer Treat Rev. 2020 Jun;86:102017.
- Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F,
Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I,
Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E.
Bevacizumab with or after chemotherapy for platinum-resistant
recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Ann Oncol. 2017 Aug 1;28(8):1842-1848.
- Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic
effects on angiogenesis. Circulation. 2002 Feb 12;105(6):739-45.
- Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the
search continues. Future Med Chem. 2011 Oct;3(14):1787-808.
- Hus M, Grzasko N, Szostek M, Pluta
A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W,
Morawska M, Kozinska J, Waciński P, Dmoszynska A. Thalidomide,
dexamethasone and lovastatin with autologous stem cell transplantation
as a salvage immunomodulatory therapy in patients with relapsed and
refractory multiple myeloma. Ann Hematol. 2011 Oct;90(10):1161-6.
- Lee SJ, Lee I, Lee J, Park C,
Kang WK. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors, potentiate the anti-angiogenic effects of bevacizumab by
suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.
Br J Cancer. 2014 Jul 29;111(3):497-505.
- Cordani N, Bianchi T, Ammoni
LC, Cortinovis DL, Cazzaniga ME, Lissoni AA, Landoni F, Canova S. An
Overview of PARP Resistance in Ovarian Cancer from a Molecular and
Clinical Perspective. Int J Mol Sci. 2023 Jul 25;24(15):11890.
- Wu J, Starr S. Low-fidelity compensatory backup alternative DNA repair
pathways may unify current carcinogenesis theories. Future Oncol. 2014
May;10(7):1239-53.
- Matulonis UA. The rapid evolution of PARP inhibitor therapy for
advanced ovarian cancer: Lessons being learned and new questions
emerging from phase 3 trial long-term outcome data. Gynecol Oncol.
2022 Dec;167(3):401-403.
- O’Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP Inhibitors
in Ovarian Cancer: A Review. Target Oncol. 2023 Jul;18(4):471-503.
- Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E. PARP
inhibition induces Akt-mediated cytoprotective effects through the
formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR
signalosome. Biochem Pharmacol. 2019 Apr;162:98-108.
- Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F Jr,
Sumegi B, Varbiro G. PARP-1 inhibition-induced activation of
PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem
Pharmacol. 2009 Apr 15;77(8):1348-57.
- Gallyas F Jr, Sumegi B, Szabo C. Role of Akt Activation in PARP
Inhibitor Resistance in Cancer. Cancers (Basel). 2020 Feb
25;12(3):532.
- Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell
growth and survival, via involvement of Akt signaling. PLoS One. 2018
May 15;13(5):e0197422.
- Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M,
Rütten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase
inhibitors (statins) increase endothelial progenitor cells via the PI
3-kinase/Akt pathway. J Clin Invest. 2001 Aug;108(3):391-7.
- Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G,
Escors D. PD1 signal transduction pathways in T cells. Oncotarget.
2017 Apr 19;8(31):51936-51945.
- Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin
Pathol. 2018 Mar;71(3):189-194.
- Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune
set point. Nature. 2017 Jan 18;541(7637):321-330.
- Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S,
Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli
J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V,
Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity
and safety of pembrolizumab in patients with advanced recurrent
ovarian cancer: results from the phase II KEYNOTE-100 study. Ann
Oncol. 2019 Jul 1;30(7):1080-1087.
- Cantini L, Pecci F, Hurkmans DP, Belderbos RA, Lanese A, Copparoni C,
Aerts S, Cornelissen R, Dumoulin DW, Fiordoliva I, Rinaldi S, Aerts
JGJV, Berardi R. High-intensity statins are associated with improved
clinical activity of PD-1 inhibitors in malignant pleural mesothelioma
and advanced non-small cell lung cancer patients. Eur J Cancer. 2021
Feb;144:41-48.
- Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in
patients previously treated with nivolumab for advanced non-small cell
lung cancer: An observational study. Mol Clin Oncol. 2019
Jan;10(1):137-143.
- Lim WJ, Lee M, Oh Y, Fang XQ, Lee S, Lim CH, Park J, Lim JH. Statins
Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and
β-Catenin Signaling. Cells. 2021 Sep 20;10(9):2488.
- Kansal V, Burnham AJ, Kinney BLC, Saba NF, Paulos C, Lesinski GB,
Buchwald ZS, Schmitt NC. Statin drugs enhance responses to immune
checkpoint blockade in head and neck cancer models. J Immunother
Cancer. 2023 Jan;11(1):e005940.
- Kwon M, Nam GH, Jung H, Kim SA, Kim S, Choi Y, Lee YS, Cho HJ, Kim IS.
Statin in combination with cisplatin makes favorable tumor-immune
microenvironment for immunotherapy of head and neck squamous cell
carcinoma. Cancer Lett. 2021 Dec 1;522:198-210.
- Voelker R. Pursuing an Effective Ovarian Cancer Vaccine. JAMA. 2018
Sep 4;320(9):858-860.
- Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine
Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015 Apr
16;3(2):320-43.
- Akula MK, Shi M, Jiang Z, Foster CE, Miao D, Li AS, Zhang X, Gavin RM,
Forde SD, Germain G, Carpenter S, Rosadini CV, Gritsman K, Chae JJ,
Hampton R, Silverman N, Gravallese EM, Kagan JC, Fitzgerald KA,
Kastner DL, Golenbock DT, Bergo MO, Wang D. Control of the innate
immune response by the mevalonate pathway. Nat Immunol. 2016
Aug;17(8):922-9.
- Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher
M. IL-2 costimulation enables statin-mediated activation of human NK
cells, preferentially through a mechanism involving CD56+ dendritic
cells. Cancer Res. 2010 Dec 1;70(23):9611-20.
- Gonçalves I, Cherfan P,
Söderberg I, Nordin Fredrikson G, Jonasson L. Effects of simvastatin
on circulating autoantibodies to oxidized LDL antigens: relation with
immune stimulation markers. Autoimmunity. 2009 Mar;42(3):203-8.